Follicular lymphoma

Disease ID:1228
Name:Follicular lymphoma
Associated with:0 targets
0 immuno-relevant targets
1 immuno-relevant ligands
An indolent non-Hodgkin lymphoma.
Database Links
Disease Ontology: DOID:0050873


No target related data available for Follicular lymphoma


Ligand Approved Immuno References Clinical comments
obinutuzumab  [  ( ]
Clinical Use: Initially approved to treat chronic lymphocytic leukemia (CLL) in combination with chemotherapy in patients who have received no prior therapy. In November 2012, this antibody was authorised as an orphan drug by the EMA for the treatment of CLL. Full EMA approval for CLL was granted in July 2014.
In February 2016, the US FDA expanded approval to include treatment of patients with follicular lymphoma (FL) who have relapsed after, or are refractory to, a -containing regimen. This new approval is for a combination therapy of obinutuzumab with , followed by obinutuzumab monotherapy.
Immuno Disease Comments: Approval is for a combination therapy of obinutuzumab with bendamustine, followed by obinutuzumab monotherapy.